Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters
Open Access
- 7 April 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 21 (1), 1-10
- https://doi.org/10.1186/s12885-021-08028-8
Abstract
Hand-foot syndrome (HFS) is a side effect of skin related to pegylated liposomal doxorubicin (PLD) application. Moderate to severe hand-foot syndrome (MSHFS) might have a serious impact on patients’ quality of life and treatment. However, information on risk factors for the development of MSHFS is still limited. To analyze the risk factors for PLD-induced MSHFS in breast cancer patients and constructed a logistic regression prediction model. We conducted a retrospective analysis of breast cancer patients who were treated with a PLD regimen in the Tumor Hospital of Harbin Medical University from January 2017 to August 2019. A total of 26 factors were collected from electronic medical records. Patients were divided into MSHFS (HFS > grade 1) and NMHFS (HFS ≤ grade 1) groups according to the NCI classification. Statistical analysis of these factors and the construction of a logistic regression prediction model based on risk factors. A total of 44.7% (206/461) of patients developed MSHFS. The BMI, dose intensity, and baseline Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels in the MSHFS group, as well as good peripheral blood circulation, excessive sweat excretion, history of gallstones, and tumour- and HER2-positive percentages, were all higher than those in the NMHFS group (P < 0.05). The model for predicting the occurrence of MSHFS was P = 1/1 + exp. (11.138–0.110*BMI-0.234*dose intensity-0.018*baseline ALT+ 0.025*baseline AST-1.225*gallstone history-0.681* peripheral blood circulation-1.073*sweat excretion-0.364*with or without tumor-0.680*HER-2). The accuracy of the model was 72.5%, AUC = 0.791, and Hosmer-Lemeshow fit test P = 0.114 > 0.05. Nearly half of the patients developed MSHFS. The constructed prediction model may be valuable for predicting the occurrence of MSHFS in patients.Keywords
This publication has 28 references indexed in Scilit:
- Efficient Prevention Strategy against the Development of a Palmar-Plantar Erythrodysesthesia during ChemotherapySkin Pharmacology and Physiology, 2013
- Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0Journal of the American Academy of Dermatology, 2012
- Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell CarcinomaJapanese Journal of Clinical Oncology, 2010
- Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of expertsEuropean Journal of Cancer, 2008
- Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective studySupportive Care in Cancer, 2007
- A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993)European Journal of Cancer, 2006
- Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?Annals of Oncology, 2005
- Pegylated Liposomal Doxorubicin with Vinorelbine in Metastatic Breast CarcinomaOncology, 2002
- Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties?European Journal of Cancer, 1996
- Erythematous Eruption of the Palms and Soles Associated with Mitotane TherapyDermatology, 1974